How Do Patients Who Fail First-Line TB Treatment but Who Are Not Placed on an MDR-TB Regimen Fare in South India? by Burugina Nagaraja, Sharath et al.
How Do Patients Who Fail First-Line TB Treatment but
Who Are Not Placed on an MDR-TB Regimen Fare in
South India?
Sharath Burugina Nagaraja
1*, Srinath Satyanarayana
2, Sarabjit Singh Chadha
2, Santosha Kalemane
3,
Jyoti Jaju
1, Shanta Achanta
1, Kishore Reddy
4, Vishnu Potharaju
4, Srinivas Rao Motta Shamrao
5, Puneet
Dewan
1, Zachariah Rony
6, Shailaja Tetali
7, Raghupathi Anchala
7, Nanda Kishore Kannuri
7, Anthony
David Harries
2,9, Sachdeva Kuldeep Singh
8
1Office of the WHO Representative in India, New Delhi, India, 2International Union Against Tuberculosis and Lung Diseases (The Union), Paris, France, 3Impact Health
Solutions, Hyderabad, India, 4State Tuberculosis Training and Demonstration Centre, Hyderabad, Andhra Pradesh, India, 5State Tuberculosis Cell, Directorate of Health
Services,Hyderabad,Andhra Pradesh, India, 6MedecinssansFrontieres,Medical Department(OperationalResearch),BrusselsOperationalCenter,Luxembourg,Luxembourg,
7Public Health Foundation of India (Indian Institute of Public Health- Hyderabad), Hyderabad, Andhra Pradesh, India, 8Central TB Division, Ministry of Health and Family
Welfare,GovernmentofIndia,NewDelhi, India,9DepartmentofInfectiousandTropicalDiseases,London School ofHygieneandTropicalMedicine,London,UnitedKingdom
Abstract
Setting: Seven districts in Andhra Pradesh, South India
Objectives: To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an
multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns
(C&DST).
Design: Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July
2008 and December 2009.
Results: There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes
were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment
success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31
(38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58
patients with negative cultures, 28 (48%) showed treatment success.
Conclusion: Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB
regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures
or drug-resistance. There are important programmatic implications which need to be addressed.
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Introduction
In India, out of the 1.2 million ‘new’ cases of tuberculosis (TB)
notified in 2009, 14,991(1.8%) were reported to have failed the
first line ‘anti-TB treatment drug regimen. Similarly among
289,756 re-treatment TB cases , 11,265 (4%) failed the first-line re-
treatment drug regimen. [1].
Multi-drug resistant TB, MDR-TB (resistance to two of the
potent first line anti-TB drugs, Isoniazid and Rifampicin) is one of
the important causes for failure on TB treatment. In order to
identify such patients early and manage them with an appropriate
drug regimen, sputum specimens of all ‘new’ TB patients who are
sputum smear positive at 5 months or more after the initiation of
treatment (defined as having failed their first-line anti-TB
treatment regimen)-, should be sent for sputum Culture and Drug
Susceptibility Testing (C&DST) in an Revised National Tubercu-
losis Programme (RTNCP) accredited laboratory and patients
should be placed on a re-treatment regimen while waiting for their
C&DST results. Similarly, for ‘Re-treatment TB’ cases, sputum
samples of patients who are smear positive at 4 months or more
after the initiation of treatment (defined as having failed their first
line anti-TB treatment) should be sent for C&DST and patients
should be continued on a re-treatment regimen while awaiting the
laboratory results.
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resistance to rifampicin are considered eligible for MDR-TB
treatment, irrespective of resistance to isoniazid, streptomycin, or
ethambutol. In the absence of rifampicin resistance, patients
simply continue their re-treatment regimen to completion [2,3].
Of the 340 isolates tested by C&DST approximately 60% of the
isolates were found to be susceptible to rifampicin and were not
eligible for MDR-TB treatment, and hence were continued on the
‘re-treatment’ regimen. There is very little published information
in India on how such patient’s fare, as all of them are already
showing signs of poor response to conventional first-line anti-TB
treatment, and some of them have considerable non-rifampicin
mono or poly-drug resistance. Such information is essential to
guide the choice of continuing (or not) the current re-treatment
regimen for such patients.
We thus conducted a retrospective cohort study in Andhra
Pradesh, South India, to a) determine the treatment outcomes of
patients who fail a first line anti-TB treatment regimen and are not
placed on an MDR-TB regimen and b) relate their treatment
outcomes to culture and drug susceptibility patterns.
Methods
Study setting
The study was conducted in seven districts (with a combined
population of 18.4 million) in the state of Andhra Pradesh, South
India, which are implementing RNTCP MDR-TB treatment
services. The MDR-TB treatment services have been implement-
ed in four of these seven districts since mid 2007 and the other 3
districts since early 2008.
Study population, sampling
We selected all patients from these 7 districts who as per the
programme guidelines were assessed as having drug resistance by
C&DST at the two RNTCP accredited laboratories and were
found not eligible for treatment with an MDR-TB treatment
regimen. Patients registered during the period July 2008 to
December 2009 were included in the study.
Management of Tuberculosis patients who are not
responding to TB treatment RNTCP uses World Health
Organization (WHO) recommended disease classification and
treatment management guidelines. Patient management is guided
by type of disease, sputum smear status and history of previous TB
treatment as recommended by WHO. Table 1 shows the
categories of TB treatment regimens used for the treatment of
TB under RNTCP. Reporting of TB treatment outcomes is done
in a standardized manner (Table 2). All patients are treated under
the supervision of a Direct Observation Treatment (DOT)
provider. All doses during intensive phase are supervised, whereas
during the continuation phase, only the first dose of the week is
supervised while the remaining two doses are self administered by
the patients themselves. Treatment adherence is assessed by
verifying blister packs. While on treatment, patients undergo
follow-up sputum examination at the end of intensive phase, two
months into the continuation phase and at the end of treatment to
assess the response to drug therapy. Any new patient who is
sputum smear positive at five months or more after the initiation of
therapy (initial treatment failures) and any re-treatment TB patient
who is sputum smear positive four months or more after the
initiation of therapy (re-treatment failures) are assessed for the
presence drug resistance in an RNTCP accredited C&DST
laboratory.
Culture and Drug Susceptibility testing
The Intermediate reference laboratory at Hyderabad (Govern-
ment sector) and Blue Peter research centre laboratory, Hyder-
abad were the culture and drug susceptibility testing (DST)
laboratories that performed the DST. All the samples were
collected by trained staff and transported to the laboratories in 1%
cetylpyridium chloride (CPC) solution. These laboratories main-
tain a register to document the receipt of sputum specimens and
the results of the C&DST.
These laboratories were accredited by RNTCP. Accreditation
involves a pre-accreditation visit by a team of experts from the
Tuberculosis Research Center (TRC), Chennai (a WHO Supra-
National reference laboratory) which looks at the adherence of the
Table 1. Treatment regimens and times of follow-up sputum smear examinations in the Indian Revised National Tuberculosis
Control Programme.
Category of
Treatment Type of patient Treatment regimens***
Follow-up sputum
examination
Intensive Phase Continuation phase
Category I New sputum smear positive 2(H3R3Z3E3)4 ( H 3R3)2
nd,4
th and 6
th month
New seriously ill sputum smear-negative*
New seriously ill extra –pulmonary*
Category II Sputum smear positive Relapse 2(H3R3Z3E3S3)+1(H3R3Z3E3)5 ( H 3R3E3)3
rd,5
th and 8
th month
Sputum smear positive failure
Sputum smear positive Treatment after default
Others
Category III New sputum smear-negative not seriously ill** 2(H3R3Z3)4 ( H 3R3)2
nd month and 6
th month
New sputum extra pulmonary not seriously ill**
*In children, seriously ill sputum smear-negative Pulmonary Tuberculosis (PTB) includes all forms of sputum smear-negative PTB other than primary complex. Seriously
ill extrapulmonary tuberculosis (EPTB) includes TB meningitis (TBM), disseminated TB, TB pericarditis, TB peritonitis and intestinal TB, bilateral extensive pleurisy, spinal
TB with or without neurological complications, genitourinary TB, and bone and joint TB.
**Not seriously ill sputum smear-negative PTB includes primary complex. Not seriously ill EP-TB includes lymph node TB and unilateral pleural effusion.
***Prefix indicates month and subscript indicates thrice weekly.
doi:10.1371/journal.pone.0025698.t001
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programme. The identification of Mycobacterium tuberculosis strains is
based on growth rate, morphology, and susceptibility to para-
nitrobenzoic acid. For drug susceptibility, the proportion method
on Lowenstein-Jensen (LJ) is used for standard anti-tuberculosis
drugs (isoniazid, streptomycin, rifampicin and ethambutol) and
tested using standard procedures. For quality assurance, the
standard Mycobacterium tuberculosis H37Rv strain was used. Both the
laboratories had passed proficiency testing which involves re-
testing and panel testing. The performance of both the
laboratories was satisfactory as determined by standard concor-
dance of .95% for Isoniazid and rifampicin and .90% for
streptomycin and ethambutol. The laboratories also participated
in the periodic proficiency testing programmes being conducted by
a supra national laboratory (Tuberculosis Research Centre,
Chennai).
Data collection and analysis
We reviewed a) the laboratory registers at the C&DST
laboratories which are the reference laboratories, b) the culture
& DST register at district level which indicates the referrals made,
and c) and the TB treatment cards and TB registers at sub-district
level in which are documented the treatment outcomes. A line- list
of all patients who had their C&DST done during the study period
and whose DST results showed no resistance to rifampicin was
prepared after ensuring the correctness of the records. Patients
with negative C&DST results or no-growth on C&DST were also
included in this data base. We collected baseline demographic
data, the C&DST results and treatment outcomes of these line
listed patients. The treatment outcomes that are reported for all
cases in this study are a result of treatment with ‘retreatment
regimen’. The data were cross verified by two investigators and
compared for consistency; once it was found to be correct the data
were entered in the Microsoft excel 2003. All variables were
described by proportions and differences between independent
groups were compared using Chi-square test and Fisher exact test
as applicable by Epi-info software. Treatment outcomes were
grouped as successful and adverse (death, failure, default and
transferred out) and patients in each of these groups were
compared. A ‘p value’ less than 0.05 were taken as statistically
significant.
Ethics approval
The study was approved by the ethics committee of the Public
Health Foundation of India and the Ethics Advisory Group of The
International Union Against Tuberculosis and Lung Disease, Paris,
France. The study was determined to be a retrospective audit of the
programme surveillance data in its records and reports, and
permission was obtained from the programme managers at the state
and national levels to access these data. Individual patient consent
was deemed un-necessary by both the ethics committees. Electronic
databases created for this analysis were stripped of personal health
identifiers and maintained securely.
Results
Characteristics of the study population
There were 204 patients who fulfilled the study eligibility
criteria of whom 2 patients could not be identified in the
tuberculosis register and were subsequently excluded from the
analysis. Of the remaining 202 patients, 58 failed a Category I
treatment regimen, 139 patients failed a Category II treatment
regimen and 5 patients failed a Category III treatment regimen.
The median age of the patients was 35 years (range 9–70 years)
and there were 143 (70%) males. All patients were treated with the
recommended RNTCP re-treatment regimen.
Treatment outcomes of the study population
Treatment outcomes as a result of initiating/continuing all
patients on a re-treatment regimen are shown in Table 3. Among
the 202 patients, the overall treatment success rate (cured or
treatment completed) was 34%. The majority of the patients either
failed the treatment again (42%) or died (18%). The treatment
success rate of patients who failed a Category II treatment regimen
(27%) was worse than patients who failed a Category I (47%) or
Category III treatment (60%). Among the 15 patients who were
below the age of 18 years, the treatment success rate was only 27%
and majority of those with an adverse outcomes failed treatment
(60%).
Relationship between treatment outcomes and C&DST
patterns
Results of treatment outcomes in relation to C&DST are shown
in Table 4. Of patients who failed a Category I and II treatment
regimen (n=197), 140 (71%) were culture positive with a DST
pattern and 57 (29%) were culture negative. Among the 140
culture positive patients with a DST pattern, the treatment success
rate was considerably worse among the patients with any drug
resistance pattern (15%) compared with patients who had pan-
sensitive organisms (37%). High failure rates were found among
patients with any drug resistance (47%) compared with those who
had pan-sensitive organisms (41%).
Table 2. Definitions of treatment outcome.
Cured: Initially sputum smear-positive patient who has completed treatment and had negative sputum smears, on two occasions, one of which was at the end of
treatment.
Treatment completed: Sputum smear-positive patient who has completed treatment, with negative smears at the end of the intensive phase but none at the end of
treatment. Or: Sputum smear-negative TB patient who has received a full course of treatment and has not become smear-positive during or at the end of treatment.
Or: Extra-pulmonary TB patient who has received a full course of treatment and has not become smear-positive during or at the end of treatment.
Treatment success: includes cured and treatment completed together.
Death: Patient who died during the course of treatment regardless of cause
Failure: Any TB patient who is smear positive at 5 months or more after starting treatment. Failure also includes a patient who was treated with Category III regimen
but who becomes smear positive during treatment.
Defaulted: A patient who has not taken anti-TB drugs for 2 months or more consecutively after starting treatment.
Transferred out: A patient who has been transferred to another Tuberculosis Unit/District and his/her treatment outcome is not known.
doi:10.1371/journal.pone.0025698.t002
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had a pan-sensitive organism, 1 had a strain with streptomycin
mono-resistance, 1 a strain with isoniazid mono-resistance and 1
had negative C&DST pattern (not included in table 4). All patients
(n=3) with negative or pan-sensitive C&DST patterns had
successful treatment outcomes.
Discussion
This study shows that overall treatment outcomes of patients
who fail a first line anti-TB treatment and who are not placed on
an MDR-TB regimen are unacceptably poor. The worst outcomes
were seen among category I and II failures placed on a re-
treatment regimen. The findings have the following programmatic
implications.
First, only one in three patients had treatment success on the
current RNTCP re-treatment regimen. Thus, irrespective of drug
sensitivity patterns, patients who fail on first line treatment in India
have poor treatment outcomes if continued on the ‘re-treatment
regimen’. Similar studies have been documented from other parts
of the world [4] [5].
Second, under ideal conditions, failure in a well-run NTP
should be infrequent in the absence of MDR-TB. The occurrence
of failure is generally linked to programme factors such as poor
adherence to treatment or poor drug quality [6]. We do not think
that drug quality is a problem as RNTCP has well defined
guidelines and drug procurement follows World Health Organi-
zation (WHO) pre-qualification criteria [7]. Although, we do not
believe that adherence to treatment is a core problem, it may be
necessary to consider measures, such as intensive supervision by
supervisory staff which includes random blister pack checks of at
least 50% of registered TB patients in a cohort every quarter until
the outcome is declared, regular community driven patient
provider meetings, periodic counseling for patients by counselors,
timely incentives to DOT providers, introducing directly observed
treatment even during continuation phase and treatment adher-
ence review by local community leaders, as these may have an
influence on the poor outcomes. The health care delivery systems
Table 4. Treatment outcomes and drug susceptibility patterns for first line anti-TB drugs amongst Patients who failed Category I
and Category II anti-TB treatment and who did not receive an MDR-TB treatment regimen in Andhra Pradesh, India (July 08 to
December 09).
Sensitivity Pattern
Treatment
Success Failure Died Default Transfer out Total p value
No. (%) No. (%) No. (%) No. (%) No. (%) No.
Pansensitive 29 (37) 32 (41) 11 (14) 6 (8) 1 (1) 79 Reference
$
Any resistance 9 (15) 28 (47) 17 (29) 5 (8) 0 (0) 59 0.005
#
Resistant to S* only 3 (33) 3 (33) 3 (33) 0 (0) 0 (0) 9 1.0
1
Resistant to H* only 3 (15) 9 (45) 6 (30) 2 (10) 0 (0) 20 0.06
#
Resistant to H and S 0 (0) 9 (64) 4 (29) 1 (7) 0 (0) 14 0.004
1
Resistant to H and E* 0 (0) 2 (50) 0 (0) 2 (50) 0 (0) 4 0.29
1
Resistant to S and E 1 (25) 2 (50) 1 (25) 0 (0) 0 (0) 4 1.0
1
Resistant to SHE 2 (25) 3 (37.5) 3 (37.5) 0 (0) 0 (0) 8 0.7
1
Negative 27 (47) 21 (37) 7 (12) 2 (4) 0 (0) 57 0.21
#
NTM* 0 (0) 1 (50) 1 (50) 0 (0) 0 (0) 2 0.53
1
*S-Streptomycin, H-Isoniazid, E-Ethambutol, NTM-Non tuberculosis mycobacterium;
#Chi square test;
1Fisher exact test.
$(In order to calculate ‘pv a l u e ’ treatment success is compared with other outcomes.
doi:10.1371/journal.pone.0025698.t004
Table 3. Treatment outcomes of TB patients who failed a first line anti-TB treatment and were not placed on MDR-TB treatment
regimens, Andhra Pradesh, India (July 08 to December 09).
Category of treatment
Treatment
success Failure Died Default Transfer Out Total No. p value
No. (%) No. (%) No. (%) No. (%) No. (%)
Category I Failures 27 (47) 20 (34) 7 (12) 4 (7) 0 (0) 58 Reference
$
Category II Failures 38 (27) 62 (45) 29 (21) 9 (6) 1 (1) 139 0.008*
Category III Failures 3 (60) 2 (40) 0 (0) 0 (0) 0 (0) 5 0.45**
Total 68 (34) 84 (42) 36 (18) 13 (6) 1 (0) 202
*Chi-square test,
**Fisher exact test.
$(In order to calculate ‘pv a l u e ’ treatment success is compared with other outcomes).
doi:10.1371/journal.pone.0025698.t003
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more accountable for TB treatment outcomes.
Third, current RNTCP treatment guidelines stipulate that
patients with failure are continued or are retreated with the ‘re-
treatment regimen’. The programme must urgently re-evaluate
this treatment strategy especially in patients without pan-sensitive
organisms or in whom there are negative cultures. There is limited
information in the published literature on how best to manage
such patients. A possible option would be to screen such patients at
more frequent intervals (for example, every month) using rapid
diagnostic technology to ascertain if they have developed
rifampicin resistance or not. If they do develop rifampicin
resistance, they could then be changed to the MDR-TB treatment
regimen. However, this proposed strategy has serious feasibility
challenges. The recent introduction of GeneXpert into the market
which allows detection of Rifampicin drug resistance within two
hours is promising but is unlikely to be available at wide level for
some time to come [8]. An alternative and rather immediate
option would be to consider shifting all patients without pan-
sensitive organisms and negative cultures to an MDR-TB
treatment regimen upfront. This seems a logical option if the
TB Programme is to give such patients the best possible chance of
‘‘treatment success’’. This is also in line with current WHO
guidelines about how to manage this problem [6].
Finally, the entire approach of using the category II re-
treatment regimen, in our opinion, merits urgent review.
According to current practice, the retreatment regimen involves
adding one new drug (streptomycin) to an already failing regimen.
This contradicts the basic principle that at least four drugs to
which the TB bacilli are sensitive are needed to ensure effective
cure and prevent the development of drug resistance [6,9]. The
current re-treatment regimen would seem in these circumstances
to be at high risk of constituting dual or mono-therapy and as such
is likely to amplify background or developing drug resistance. If
this drug resistance pressure involves rifampicin and isoniazid, the
practice may create new MDR-TB cases. The individual and
public health implications including the further transmission of
MDR-TB to households, health staff and the community are
serious.
The strengths of this study are as follows: large numbers of
district records were carefully reviewed and outcomes verified
using patient cards; the findings come from the programme setting
and are thus likely to reflect the operational reality on the ground;
C&DST results were quality controlled; and we adhered to
STROBE guidelines on reporting [10]. The limitations of the
study are that C&DST patterns were not available for a
proportion of patients and these patients were thus labeled DST
negative. This reflects the current difficulties of ‘‘culture yield’’
related to current DST techniques. We also do not know why
patients with pan-sensitive organisms had relatively poor out-
comes, and this observation merits further investigation. Although
our cohort also involves seven districts in Andhra Pradesh, the
cohort is relatively small and these findings merit further validation
using larger programme data-sets including other states in India.
This would validate these findings and inform national policy in a
robust manner.
In conclusion, overall treatment success rates in failure patients
placed on a re-treatment drug regimen are poor and these results
need to be urgently reviewed. One of the immediate logical
options particularly for patients who fail re-treatment category II
regimens would be to start on an empiric MDR-TB regimen until
C&DST results become available.
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